Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
Introduction Antibody-drug conjugates (ADCs) consist of antibodies, linkers, and cytotoxic payloads. Compared to traditional chemotherapy, ADCs target tumors with the promise of reducing systemic toxicity, providing a broader therapeutic window and a higher therapeutic index. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary … Read more
In today’s circuit design, the vast majority of scenarios involve mixed-signal circuit designs that integrate both digital and analog components, and the intermediate connection channels in mixed circuits inevitably rely on ADC and DAC. For example, the joystick inside our daily remote controls operates on the principle of a sliding potentiometer. Some higher-end designs use … Read more
Author | Little Fish Periodically, major pharmaceutical media and authoritative journals summarize the development of ADCs. Recently, a review on ADCs published by the internationally renowned journal ACS caught our attention. As a member of CAS (American Chemical Society), Janet M. Sasso’s team innovatively used patents and articles related to ADCs within CAS as data … Read more
Representative ADC Technology Platforms As a combination drug, any component of an ADC can be replaced or modified.Therefore, the ADC combination technology platform has significant extensibility, allowing for the iterative combination of a rich variety of products.The development history of internationally leading ADC companies is rooted in having a competitive platform.Table 1 lists several representative … Read more
Known as magic bullets, ADCs have been highly praised in recent years. The design concept of these drugs is clear: to utilize the high specificity of antigen-antibody binding to selectively deliver toxins to antigen-positive cells, thereby selectively killing target cells and reducing damage to normal cells. However, like other drugs, the actual performance of ADCs … Read more
Introduction Antibody-Drug Conjugates (ADCs) are targeted therapies that consist of antibodies, linkers, and cytotoxic drugs, using monoclonal antibodies as carriers to efficiently deliver cytotoxic drugs to target tumor cells in a targeted manner, combining the powerful killing effect of traditional chemotherapy with the tumor-targeting capability of antibody drugs. An ideal ADC maintains stability in the … Read more
Source: Xiaoyao Shuo Yao Introduction Antibody-drug conjugates (ADC) are a powerful cancer treatment method that combines monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs linked by a linker. ADCs utilize the specificity of antibodies for their target antigens, combined with the potency of cytotoxic drugs, to selectively kill tumor cells expressing the target … Read more
Antibody-Drug Conjugates (ADCs) are one of the fastest-developing treatments in the field of oncology, with 15 ADCs already approved and over 210 currently undergoing clinical trials. In recent years, the development of ADC drugs has entered a flourishing phase, especially demonstrating significant efficacy and good safety profiles against targets such as HER2, EGFR, Trop2, CLDN18.2, … Read more
Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin, trade name: Mylotarg) was approved for the treatment of CD33-positive acute myeloid … Read more